Ten News Live

Highest Inter Terminal Movement of Trailers Recorded in the Month of May

Business Wire India
Inter Terminal Transfer of Tractor trailers was introduced between JNPCT and GTI (vice-a-versa) initially with effect from 13.02.2015 and between JNPCT & NSICT (vice-a-versa) from 24.03.2015.
 
Since the commencement of ITT, till date 1.9 lac trucks have exchanged between the terminals while carrying out 2.4 lac transactions reducing congestion on roads outside port terminals (that many containers with one less ENTRY and less EXIT activity). 16660 trucks with 20029 transactions were recorded in the month of May, which is the highest monthly transfer till date.

The system has resulted in the following benefits to the Transporters/ Users:
 

  • One ENTRY and one EXIT to a particular terminal is reduced in the whole process, thus resulting in reducing the load on the terminal gates for productive moves with no physical transactions.
  • Reduces number of tractor-trailers on approach roads leading to terminal gates thus reducing congestion.
  • Optimum utilization of trucks. Truck will always carry a container on its return journey.
  • Saving in fuel thus conserving energy and reducing pollution to that extent. During each trip, 15 km of travel is reduced leading to saving in fuel of 7.5 liters of diesel.
  • Turnaround time of trucks is reduced thereby increasing number of trips between CFS and Port Terminals.
  • Cost of handling is reduced. More number of containers are moved in less time.

Uflex Leads the World Against Counterfeiting at DRUPA Germany

Business Wire India
The issue has been giving sleepless nights to brands owners. The fall out can be colossal. Brands cannot afford to let go their hard earned reputation down the drain. The panic buttons have been pressed. Yes! We are talking about the modern day enemy – ‘COUNTERFEITING’, that has left brands more vulnerable and perplexed than ever.
 
According to a recent research report by a leading brand management consultancy, counterfeiting now costs more than 2% of the global economic output that works out to around $1.8 trillion a year. The dark underbelly of counterfeiting is expanding by over 15% every year, which is alarming. Consumer goods account for over 46% of the counterfeiting trade.
 
India’s largest global flexible packaging solution company Uflex has been relentlessly working over the last two decades to develop brand protection and anti-counterfeiting solutions that prevent look-alikes from eroding brand equity of its clients. Company’s brand protection solutions have created quite a stir in the market with more and more brands now opting for them.
 
The growing demand is evident at DRUPA with prospective customers making a beeline at the Uflex pavilion to understand the wide range of solutions that can save their brands from being duplicated.

 

Waging a full blown war against counterfeiting, Uflex has exhibited the most contemporary brand protection solutions at its pavilion at DRUPA. There is a tremendously encouraging response for:
 

  • UV Process Manufactured Fresnel, Diffractive, Holographic and Hybrid (Combination) lens embossed films;
  • Holographic Thermal Lamination Film;
  • Stamping Foils

 
Packaging films combining prismatic (Fresnel) structures with holographic patterns in customized designs and shapes yield the most creative packaging film options. Packaging designers integrate the dynamic 3D lensing and holographic effects of Uflex film to enhance the look and salability of the final package. With the help of latest re-combiners, Uflex is able to make masters with customized pattern designs.
 
Holographic thermal lamination films are available in Polyethylene Terephthalate (PET) and Bi-axially Oriented Poly Propylene (BOPP) variants in generalized and customized designs. Ease of lamination on paper board makes thermal films very unique as this film does not leave spots on the substrate, which otherwise are distinctly visible in the dry lamination process.
 
Uflex is a market leader in producing metallic/ holographic stamping foils that are widely used for printing, packaging and textile industry enhancing visual appeal and offering superior brand protection at the same time. Uflex has developed stamping foils formulations that ensure high degree of consistency and reliability. These foils are available in silver, gold and a variety of metallic hues. With a right blend of creative expertise, infrastructure and technical capabilities Uflex delivers foils with superior shine, brilliance and durable impression.
 
Strong R&D quotient coupled up with extensive market knowledge and feedback received from clients enables Uflex deliver high quality foils adhering to international standards. The flexible packaging major has the required capabilities to meet critical requirements in terms of substrate application, designs and colour matching. Colours can be really tricky and the pantones often do not work out as prescribed by the customers. Uflex has the skills, capabilities and experience to match the exact pantone and render foils completely in line with the requirements of the customers.   
 
Also on display at DRUPA are different types of Holograms {analog 2D/3D conventional, Dot matrix (up to 24,000 DPI); non-diffractive Litho (up to 1,20,000 DPI) and E-Beam}; Unigrams; Latentograms; Wide Web Holographic Films {Soft embossing films, Hard embossing films, UV embossing films, High Refractive Index films, Windows/ Demetalized and Lens films}. A lot of customers at DRUPA are also expressing keen interesting Holographic Pouches, Holographic Strips, Holographic Scratch, Holographic Wads, Holographic Shrink Sleeves; Labeling solutions using foils, Fresnel lens and holographic effects {Printed Labels, Tamper Evident Security Labels, Anti-counterfeit Labels, Bar-Code Labels, Scratch Labels, Thermal Transfer Labels, Serial Number Labels, Holographic Labels}; Hot and Cold Stamping Foils and OEKOTEX Certified Textile Value Addition Products {Sequins Film, Hot Melt Film, Holographic Glitter Film} etc.
 
Mr. Ashok Chaturvedi, Chairman and Managing Director, Uflex Limited who is currently with his team at DRUPA said, “Being a first generation entrepreneur I can completely understand the hard work and toil that goes into building a brand. It is absolutely important to protect the image and equity of brands from being counterfeited. With the advent of technology, the counterfeiters are also leaving no stone unturned to ‘Make The Fake’. Uflex’s principle of innovation to create value added differentiation is truly demonstrated by its technologically superior anti-counterfeiting solutions. I am glad by the response that we have been getting for our brand protection solutions.”

Uflex is in Hall No. 15 at Stand No. C 51 from May 31 to June 10, 2016

About Uflex
 
Uflex is India’s largest end-to-end flexible packaging company and an emerging global player. Since its inception back in 1983, Uflex has grown from strength to strength to evolve as a truly Indian Multinational with consumers spread across the world. Uflex today has state-of-the-art packaging facilities at multiple locations in India with installed capacity of around 100,000 TPA and has packaging film manufacturing facilities in India, UAE, Mexico Egypt, Poland and USA with cumulative installed capacity in excess of 337,000 TPA.
 
All Uflex plants are accredited with ISO 9001, 14001, HACCP & BRC certifications. Uflex caters to markets spanning across the globe in over 140 countries like USA, Canada, South American countries, UK and other European Countries, Russia, South Africa, CIS, Asian and African nations. Integrated within its core business profile are allied businesses like Engineering, Cylinders, Holography and Chemicals which further give Uflex a superior edge above competition.
 
Uflex Limited is also a part of the D&B Global Database and winner of various prestigious national and international awards for its products’ excellence. Uflex offers technologically superior packaging solutions for a wide variety of products such as snack foods, candy and confectionery, sugar, rice & other cereals, beverages, tea & coffee, dessert mixes, noodles, wheat flour, soaps and detergents, shampoos & conditioners, vegetable oil, spices, marinates & pastes, cheese & dairy products, frozen food, sea food, meat, anti-fog, pet food, pharmaceuticals, contraceptives, garden fertilizers and plant nutrients, motor oil and lubricants, automotive and engineering components etc.
 
Some of Uflex’s clients on the global turf include P&G, PepsiCo; Tata Global; Mondelez, L’ Oreal, Britannia, Haldiram’s, Amul, Kimberly-Clark, Ferro Rocher, Perfetti, GSK, Nestle, Agrotech Foods, Coca-Cola, Wrigley, Johnson & Johnson among others.

Website: www.uflexltd.com

Photo Caption: Anti-counterfeiting solutions by Uflex at DRUPA

Amity Boosts Online Certification in India

Business Wire India

Online Certification is an enabling digital gateway for learners to imbibe knowledge and enhance skills in chosen disciplines largely through self-learning, hands-on engagement, peer and teacher interaction, and industry interface. An innovative knowledge boosting and career up-skilling platform, Online Certification offers effective and convenient learning opportunities, often allowing students to scale up the certification to acquire higher academic degrees. From live interactive classes to group engagement to project collaboration – Online Certification empowers learners as they aspire for industry recognized or endorsed certificates.

With the Digital Revolution relentlessly expanding the horizon of the possible, each day we negotiate with the sound and fury of change. One way to manage change and make sense of the new is to keep on learning. Fortunately, now learning can happen anytime from anywhere using almost any smart communication device. And, recognizing the endless possibilities of digitally driven learning, education institutions are offering online courses unimpaired by geography, time zones, and learning platforms. With its multi-pronged approach to learning, Online Certification is increasingly gaining traction among educators and learners from very different backgrounds.

As the education ecosystem witnesses this rising trend – the popularity of Online Certification across disciplines and for professional enhancement – there is a BIG question to be addressed. Will the digitally enabled Online Certification gradually take the place of the traditional brick-and-mortar driven college degree? No easy answers to this one, but let’s see.

First, we look at the contemporary learning ecosystem. For years represented by the traditional classroom model, today education leads a parallel vibrant life outside physical walls! Education has transformed into learning that is immediate, self-driven, and on-the-move: an incessant activity warranting constant learning and evolution. Side by side, one witnesses the rising cost of traditional classroom courses, lengthy tenure of study, and lack of appropriate jobs post degree acquisition. So, more and more students are attracted to short and economical certificate courses in addition to college degrees. And, others are seeking out certificates to reinforce existing degrees, for enhancing existing capabilities, to get noticed in their professional circles, or for new and better employment opportunities.
 
Second, the numbers one comes across in reports, surveys, and studies are quite revealing. Home to around 1.3 million learners in the online education space, according to recent estimates, India is globally ranked third in terms of online learning market size. With Online Certificate courses encouraging working professionals to acquire new skills and know-how, business functions like Digital Marketing, Project Management, and Big Data Analytics are witnessing enormous demand for knowledgeable and skilled workforce. Experts opine, given the trend, the value of the online education market in India is set to reach $40 billion by 2017 from the current $20 billion.
 
As Ajit Chauhan, Vice-Chairman of Amity Online Education, says, ‘Enrollments in Online Certificate programs continue to increase year-on-year. For instance, over the past one year, it has grown more than thirty per cent. Realizing the potential and effectiveness of Online Certification, Corporate India is becoming progressively inclined to utilize e-Learning for employees across professions. As learners increasingly focus on career advancement, we witness strong growth in online professional degree programs. We expect to see accelerated growth in online learning over the next 2-3 years'
 
Here, a quick review of two popular Online Certification courses is worthwhile for they offer interesting takeaways.
 
Over the last few years, Marketing via digital platforms and by using online tools has gained popularity and is now widely practiced across industries. If only our Internet-enabled message inboxes could speak up! Recognizing this change in marketing strategy and focusing on providing a comprehensive learning experience, Amity Certified launched its Digital Marketing course. Taking a hands-on approach, the course enables learners to acquire new skills and gain work exposure by executing campaigns via real-life projects. The three-month course covers a range of Digital Marketing domains and tools, offers real-life experience through projects, teaches ways to plan and implement effective campaigns, and helps learners prepare for leading digital marketing certifications. From Search Engine Optimization to Web Analytics to Content, Mobile, Email, and Social Media Marketing – learners gain practical insights on innovative strategics in online marketing to connect with new waves of the Internet-based audience.
 
Talking about Amity Online Education, in the last one year, the platform has trained thousands of working professionals from different industry backgrounds through Online Certificate courses. These programs are delivered either through online self-learning or via live online instructor-led training. Amity Online also received hundreds of registrations per month for courses ranging from Web App Programming and IT Security Management to Financial Management. So, one gets a sense of the rising popularity of Online Certification in India!
 
Now Project Management is another professional domain that is expected to open up over 15 million jobs by 2020. Again, sensing the need to provide a well-researched and industry-vetted learning experience, a three-month course in Project Management was launched by Amity Certified. A well-recognized skill enhancement program, the program covers the fundamentals of implementing standard processes and practices in projects, teaches ways to deliver projects faster at reduced cost and with high business value, and helps learners prepare for CAPM© certification.

Talking about enrollment of the learners in the past one year, Mr. Ajit Chauhan, Vice Chairman of Amity Online Education explains, “Amity Online Education’s courses are geared towards empowering students, job aspirants, working professionals, and entrepreneurs across industries. The e-Learners aged 21–45 are mostly from the metros. But we are also getting encouraging response from non-metros and Tier II and Tier III cities. The applicants are young professionals who want to append additional skills to their profile and look for quick career advancement. Alongside mid-level managers, we have candidates facing career stagnation. Online Certification enables both to cultivate actionable business intelligence in their work. Individuals who want to rejoin the workforce, for example, female employees who have been on maternity and personal breaks, are also pursuing Online Certification courses.’
 
Research literature reveals that an increasing number of individuals, institutions, companies, and businesses are turning to e-Learning. Now, more than ever before, e-Learning courses and online training programs are being sought for personal and professional education. In India, e-Learning holds immense potential and is poised for exponential growth in the near future. Effective and convenient, Online Certification, in particular, has ignited the imagination of the 21st century learner in India!
 
For admissions, please visit: amitycertified.com

Expo 2020 Dubai Connects with Etisalat for Fastest, Smartest Site on Earth

Business Wire India

The site of Expo 2020 Dubai will be one of the fastest, smartest, and best connected places in the world during the global mega event, through its Premier Partnership with Etisalat Group.

 

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160605005072/en/

 

Etisalat Group has been awarded the Telecommunications and Digital Services Premier Partnership for  ...

Etisalat Group has been awarded the Telecommunications and Digital Services Premier Partnership for Expo 2020 Dubai (Photo: ME NewsWire)

Her Excellency Reem Al Hashimy, UAE Minister of State for International Cooperation and Director General Bureau Expo Dubai 2020 welcomed the Premier Partnership with Etisalat. “Communications that took 6 weeks in 1851, when the first Expo took place, now take 6 microseconds. Ours is a hyper-connected age, and Etisalat plays a critical role in linking people and their technology so that they can connect and share, innovate and create. With its international reach, and expertise, Etisalat is well placed to support us in making Expo 2020 Dubai the best connected site on Earth during the mega event.”

 

Saleh Al Abdooli, Chief Executive of Etisalat Group said, “In a world where digital technologies are redefining the way people interact, live and work, creating a borderless and inclusive global community, Etisalat is honoured to have the opportunity to contribute to the Expo 2020 Dubai. As part of the partnership, we aim to bring together our people, technologies and expertise in telecommunications and digital services and solutions for an on-time execution of complex projects.”

 

The partnership between Expo 2020 Dubai and Etisalat has a key role in the delivery of the mega event. From July this year, Etisalat will be involved in creating the infrastructure for the Expo site – enabling Expo 2020 Dubai to provide visitors and participants with a cutting edge, immersive digital experience that brings the Expo themes to life for the 25 million expected visitors. Etisalat will also provide on-site Wi-Fi capable to handling up to 300,000 people onsite in a day.

 

Etisalat will have global rights as Expo’s Official Telecommunications and Digital Services Partner, including the 18 countries that the company currently operates in. Etisalat and Expo are also exploring possibilities for a presence on the site in the post event phase, as part of a long lasting legacy centred on the stimulation of a knowledge economy and innovation hub

 

*Source: ME NewsWire

 

 

 

 

MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20160605005072/en/

DURVALUMAB MONOTHERAPY DEMONSTRATES EFFICACY IN UROTHELIAL BLADDER CANCER

Business Wire India

AstraZeneca and its global biologics research and development arm, MedImmune, announced efficacy and safety data for durvalumab, a selective programmed-death ligand-1 (PD-L1) antibody, in patients with advanced urothelial bladder cancer (UBC).1

 

Preliminary results of the Phase I/II trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showed an objective response rate (ORR) of 31% in all evaluable patients (95% confidence interval (CI): 18%-47%) and 46% (95% CI: 28%-66%) in patients with PD-L1-high-expressing* tumours.1 Disease control rate (DCR), defined as confirmed complete or partial response or stable disease for 12 or more weeks, was 48% (95% CI: 32%-64%) in all evaluable patients, and 57% (95% CI: 37%-76%) in patients with PD-L1-high-expressing tumours.1 Median duration of response had not yet been reached.1

 

David Berman, Senior Vice President, Head of Oncology Innovative Medicines at MedImmune, said: “The efficacy data for durvalumab monotherapy in second-line bladder cancer are very encouraging, and confirm confidence in our diagnostic assay where the magnitude of response to durvalumab is clearly linked to PD-L1 expression. We look forward to continued exploration of durvalumab’s potential in our first-line bladder cancer trial, DANUBE, both as monotherapy and in combination with tremelimumab.”

 

Durvalumab 10mg/kg was administered every two weeks intravenously for up to 12 months, and demonstrated a manageable safety profile among all patients (n=61).1 The most common adverse events reported in 5% or more of patients were all grade 1 or 2: fatigue (13%), diarrhoea (10%), decreased appetite (8%), arthralgia (7%), asthenia (7%), nausea (7%) and pyrexia (7%).1 Three patients experienced treatment-related Grade 3 adverse events (1 acute kidney injury, 1 infusion-related reaction and 1 tumour flare).1

 

Dr. Christophe Massard, Head of Early Clinical Trials at the Institut Gustave Roussy, Villejuif, France, said: “These positive preliminary data continue to support durvalumab’s clinical efficacy and safety profile for the treatment of bladder cancer, and confirm durvalumab as a potential breakthrough therapy for a patient population with enormous unmet need.”

 

*PD-L1-high expression is defined as 25% or more PD-L1 staining in tumour cells (TCs) or immune cells (ICs) as assessed through use of the Ventana SP263 diagnostic assay1.

 

In 2016, durvalumab received Breakthrough Therapy Designation by the U.S. Food and Drug Administration as a potential treatment for patients with PD-L1 positive inoperable or metastatic UBC.2 Durvalumab is also being studied as monotherapy or in combination with tremelimumab, in non-small cell lung (NSCLC), head and neck, bladder, gastric, pancreatic, hepatocellular carcinoma (HCC) and blood cancers, and is a pillar of AstraZeneca’s late-stage immuno-oncology programme comprising more than 7,000 patients in 19 clinical trials across tumour types.3,4

 

*PD-L1-high expression is defined as 25% or more PD-L1 staining in tumour cells (TCs) or immune cells (ICs) as assessed through use of the Ventana SP263 diagnostic assay1.

 

– ENDS –

 

NOTES TO EDITORS

 

About Durvalumab

 

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1).5 PD-L1 expression enables tumours to evade detection from the immune system through binding to PD-1 on cytotoxic T lymphocytes.5,6 Durvalumab blocks PD-L1 interaction with both PD-1 and CD80 on T cells, countering the tumour's immune- evading tactics.5 Durvalumab is being developed alongside other immunotherapies to activate the patient's immune system to attack the cancer. Durvalumab is being investigated in an extensive clinical trial programme, as monotherapy or in combination with tremelimumab, in NSCLC, bladder, head and neck, gastric, pancreatic, HCC and blood cancers.4 In 2015, durvalumab received Fast Track Designation for the treatment of patients with PD-L1–positive metastatic SCCHN,7 and in 2016, durvalumab was granted Breakthrough Designation by the U.S. Food and Drug Administration as a potential treatment in patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer.2

 

AstraZeneca’s Approach to Immuno-Oncology (IO)

 

Immuno-Oncology (IO) is a therapeutic approach designed to stimulate the body’s immune system to destroy tumours.8,9,10 At AstraZeneca, and MedImmune, our biologics research and development arm, our IO portfolio is anchored by immunotherapies that have been designed to overcome anti-tumour immune suppression.5,11 We believe that IO-based therapies will offer the potential for life-changing anti-cancer treatments for the vast majority of patients.

 

We are pursuing a comprehensive clinical trial programme that includes durvalumab (PD-L1) monotherapy and durvalumab in combination with tremelimumab (CTLA-4) in multiple tumour types, stages of disease, and lines of therapy,3 using the PD-L1 biomarker as a decision-making tool to define the best potential treatment path for a patient. In addition, the ability to combine our IO portfolio with small targeted molecules from across our oncology pipeline, and with those of our partners, may provide new treatment options across a broad range of tumours.

 

About AstraZeneca in Oncology

 

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least 6 new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.

 

By harnessing the power of four scientific platforms — immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates — and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

 

About MedImmune

 

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.

 

About AstraZeneca

 

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

 

References

 

1 Massard C et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-PD-L1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. Accepted Manuscript. To be published June 2016.

 

2 AstraZeneca. Durvalumab granted Breakthrough Therapy Designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer. 17 February 2016. Available at https://www.astrazeneca.com/media-centre/press-releases/2016/Durvalumab-granted-Breakthrough- Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.html. Accessed May 2016.

 

3 AstraZeneca. Data on File. Q1 2016 Immuno-oncology Update: Clinical Trials Appendix. 2016

 

4 AstraZeneca. Durvalumab ATLANTIC trial supports clinical activity and AstraZeneca’s overall immuno-oncology strategy. 18 December 2015. Available at https://www.astrazeneca.com/media-centre/press-releases/2015/Durvalumab-ATLANTIC-trial-supports-clinical-activity-and-AstraZenecas-overall-immuno-oncology-strategy.html. Accessed May 2016.

 

5 Stewart R et al. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer Immunol Res; 2015. Published OnlineFirst May 5, 2015; doi: 10.1158/2326-6066

 

6 Patel SP and R Kurzrock. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015;14:847-856. Published OnlineFirst February 18, 2015.

 

7 AstraZeneca. AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma. 29 February 2016. Available at https://www.astrazeneca.com/media-centre/press -releases/2016/astrazeneca-reports-top-line -result-of-tremelimumab-monotherapy-trial-in -mesothelioma-29022016.html. Accessed May 2016.

 

8 Eggermont E & Finn O. Advances in immuno-oncology. Annals of Oncology 23 (Supplement 8): viii5, 2012. doi: 10.1093/annonc/mds255

 

9 Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of Oncology 23(Supplement 8): viii6-viii9, 2012. doi: 10.1093/annonc/mds256

 

10 Melero I et al. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clin Cancer Res 2013;19:997-1008.

 

11 Bograd AJ et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother. 2011 Nov;60(11):1509-27.

 

 

 

 

Tata Communications Continues its Winning Streak at the 2016 Frost & Sullivan India ICT Awards

Business Wire India

  • Enterprise Data Service Provider of the Year (Eighth year in a row)
  • Hosted Contact Center Service Provider of the Year (Fifth year in a row)
  • Enterprise Ethernet Provider of the Year (Third year in a row)
  • Enterprise Telecom Service Provider of the Year – Large Enterprise Segment (Second year in a row)
  • Third Party Datacenter Service Provider of the Year (First time winner)
  • Enterprise VoIP Provider of the Year (First time winner – new award category)
 

Tata Communications received top honors at the 2016 Frost & Sullivan India ICT Awards banquet, with five awards in the Enterprise Telecom Services category and one award in the Enterprise Infrastructure category. Tata Communications took center stage at the award ceremony, attended by the telecom industry’s leading players, to receive four Service Provider of the Year awards for (1) Enterprise Data (2) Hosted Contact Center (3) Enterprise Telecom – Large Enterprise Segment, and (4) Third Party Datacenter. The Company also won Enterprise Ethernet and Enterprise VoIP Provider of the Year awards.
 
Benoy CS, Director, Digital Transformation Practice, Frost & Sullivan, says, “In 2015, Tata Communications continued to demonstrate its pioneering vision and leadership across the enterprise telecom and infrastructure portfolio. Its evolution has accelerated on an upward trajectory through investing in innovation and offering its enterprise customers a comprehensive value proposition and seamless service experience. Its ability to align teams to deliver this world class experience has enabled it to capture customer delight with a strong global network supporting it. With the Company’s holistic perspective on delivering an enriched customer experience, it has continued to garner appreciation and established itself as the preferred partner for enterprises in India. With its commitment to creating and enabling cutting-edge, integrated services, Tata Communications brings to the table a value proposition that is compelling, rich, and diverse and that meets the growth imperatives of the next generation enterprise.”
 

Currently in its 14th year, the 2016 Frost & Sullivan India ICT Awards witnessed the participation of leading names in the technology business. These companies were lauded for their exceptional growth and market strategies, product development abilities, competitive advancement skills, technology innovation, and dedicated customer focus in the Indian ICT sector.
  
Sumeet Walia, Head, Global Enterprise Business, Tata Communications, says, “We are truly honored to receive these prestigious awards from Frost & Sullivan, consecutively, some for 8 years in a row. Enterprises globally are in the midst of a massive digital transformation and are looking for IT services that can deliver global reach and scale, flexibility and agility and enterprise grade security. Today, Tata Communications provides services to 70% of the Fortune 500 organizations, helping them operate more efficiently with the highest quality voice, video, data and internet communications. To stay ahead of this digital transformation, we believe it is imperative for us to continuously innovate and evolve our services portfolio in keeping with the demands of the industry. These awards are testament to our innovative services portfolio and our business strategy. We’re delighted to receive this recognition and acknowledgement from Frost & Sullivan.”
  
The Accolades won by Tata Communications at 2016 Frost & Sullivan India ICT Awards:

Enterprise Data Service Provider of the Year

In 2015 the data services market was driven by the need for solutions that support multipoint connectivity, migration to cloud, big data, enabling mobile productivity and the webification of enterprise applications. Tata Communications demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers have made toward their services or products. Its strategic imperatives to offer high quality customer experience and to innovate on developing flavors of solutions for end-to-end business applications, along with its robust network backbone across the globe, helps it differentiate and be the service provider of choice for Indian enterprises.

Tata Communications has included various flavors of connectivity solutions that are based on a robust network infrastructure for high speed cloud delivery through its IZO™ platform that connects to leading cloud service providers from its datacenters. It also launched the Ultra-low power WAN solution for connected devices and Internet of Things (IoT) applications, as part of its IoT strategy. This showcases its leadership in Cloud and IOT which are the next growth engines of the enterprise ecosystem.

Tata Communications’ core strength lies in its infrastructure and innovation in its product portfolio, which helps the Company to be consistently ranked as the market leader in the data services space.

Hosted Contact Center Service Provider of the Year

Differentiation by value creation has provided Tata Communications a competitive edge in the Hosted Contact Center market. The Company has consistently enhanced the features and functionalities in its portfolio and offered customized solutions to enterprises. Its carrier grade services and unified service level agreements provide the company with a unique edge. Tata Communications has consistently maintained the market leadership position in India with the highest implementation of cloud contact center seats.

 
Through strategic partnerships, Tata Communications has created an integrated solution for its global customers, thereby enabling a seamless unified communications experience. Its focus on creating an omni-channel experience across multiple channels such as voice, video, email, chat, self-service and social media to enable context based communications has further strengthened its portfolio and go-to-market strategy.

Enterprise Ethernet Provider of the Year

The year 2015 has witnessed changes in terms of transmission speeds, uptake of cloud services and expansions in datacenter capacities, in turn fueling the adoption of Ethernet services by enterprises. Enterprises are continuing to adopt Ethernet for their mission critical applications due to the benefits that it offers – scalability, reliability, and cost-efficient bandwidth. 

Tata Communications is one of the leaders in the Ethernet service provider market, with several classes of service (CoS) ranging from Next Generation Ethernet to multiple variants in Ethernet depending on the nature of data traffic. One of the Company's key Ethernet growth strategies has been bundling its IZO™ cloud capability with its Ethernet solution. Further, the Company has also been investing in network expansion through Greenfield investments, which in turn provide fundamental growth to the Ethernet services market.

Tata Communications is widely regarded as one of the leading network providers, and its brand strength has been instrumental in positioning its Ethernet services firmly not just with its existing customer base but also in the rapid acquisition of new customers. These continued investments toward technology and expanding reach have enabled Tata Communications to retain its position as a leader in this space.

Enterprise Telecom Service Provider of the Year – Large Enterprise Segment

The large enterprise telecom market in India has been experiencing an accelerated growth over the past few years. Large enterprises are now starting to make inroads toward convergence and advanced Unified Communications solutions from legacy connectivity services. The exponential growth of connected devices, social media, analytics, and cloud computing (SMAC), and the acceptance of bring-your-own-device (BYOD), are all resulting in a major transition in the way enterprises engage with technology.

As one of the most recognized global brands, Tata Communications has led from the front in ensuring a robust digital ecosystem that is equipped for the future – with infrastructure that can cope with customers’ demands of intelligence, scalability and flexibility. Its ability to look at the customer experience holistically has assisted it to align teams to deliver customer delight by having a 360-degree view of their requirements. Its strong global presence and ambition to continue to evolve, expand, and invest in building long-term relationships with customers and partners make Tata Communications a preferred technology partner for the large enterprise segment.

Third Party Datacenter Provider of the Year

On-premise datacenter capacity requirements often outpace availability, as both data and storage needs tend to explode due to new services, applications and workloads. Tata Communications is a notable company that has taken a bold step toward addressing enterprise desire to have an on-premise like experience in a hosted datacenter with respect to security, compliance, performance, user experience, and connectivity.

The combination of its datacenter and network expertise coupled with bespoke solutions such as managed hosting, cloud, security and managed services, make it a one-stop-solution provider for hybrid deployment models. Its managed services portfolio enables infrastructure management in a lean fashion by tailoring the solution design – hardware, software and services – to fit current capacity requirement as well as to provision buffer capacity to handle spikes in application traffic. The Company’s consultative mode of engagement brings a very personal experience to datacenter services procurement, and this rich experience acquired over the years has established Tata Communications as the market leader.
 

Enterprise VoIP Provider of the Year

With an intention to curb IT spend, enterprises are slowly migrating to convergence and adopting collaborative solutions like VoIP which provide them enhanced flexibility and scalability in their infrastructure along with much-needed cost effectiveness.

Tata Communications is undertaking various strategies to make VoIP services pervasive by consistently rolling out new functionalities, expanding into new territories and growing its channel partner network. Its wide offerings and continuous innovation in the managed VoIP segment enables it to provide enterprises with high-quality voice services to on-net and off-net locations, reduce overhead costs, and provide modular flexibility. With steady investments in this technology, and frequent new offerings with high level QoS and expanding reach, Tata Communications clearly demarcates itself in this nascent segment.

Frost & Sullivan’s India ICT Awards contenders were judged based on variety of parameters including revenue, market share, product diversity, vertical and horizontal diversity, major customer acquisitions, and efficacy of innovation process, product service, and positioning, among others. The judging process involved in-depth primary interviews of various industry participants and secondary research conducted by Frost & Sullivan analysts. An elite panel of jury members comprising some of the most prominent CIOs/CTOs from the industry evaluated the compiled data and incorporated the end-user perspective. Frost & Sullivan then presented the Awards to the companies that received the number one industry rank in each category.

TATA COMMUNICATIONS and TATA are trademarks of Tata Sons Limited in certain countries. IZO is a trademark of Tata Communications in certain countries.

About Tata Communications:

Tata Communications Limited (CIN no: L64200MH1986PLC039266) along with its subsidiaries (Tata Communications) is a leading global provider of A New World of Communications™. With a leadership position in emerging markets, Tata Communications leverages its advanced solutions capabilities and domain expertise across its global and pan-India network to deliver managed solutions to multinational enterprises, service providers, and Indian consumers.

The Tata Communications global network includes one of the most advanced and largest submarine cable networks and a Tier-1 IP network with connectivity to more than 240 countries and territories across 400 PoPs, as well as nearly 1 million square feet of datacenter and collocation space worldwide.

Tata Communications’ depth and breadth of reach in emerging markets includes leadership in Indian enterprise data services and leadership in global international voice. Tata Communications Limited is listed on the Bombay Stock Exchange and the National Stock Exchange of India.

http://www.tatacommunications.com  

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. 
 
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
 

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation and implementation.  
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.  


 
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?  
 
Contact Us: Start the discussion
  
Website: http://www.frost.com
 
Twitter: @Frost_MENASA
 
Event Hashtag: #fsictawardsindia

Photo Caption:
Mr. Manish Kakkar, Head- West Region, India, Global Enterprise Solutions, Tata Communications receiving the 'Enterprise Data Service Provider of the Year' award from Mr. Keyur Desai, VP-IT Infrastructure & Projects Group, Essar Group, in the presence of Mr. Benoy CS, Director, Digital Transformation Practice, Frost & Sullivan
Mr. Ankush Gangwani, General Manager, Unified Communications and Collaboration, Tata Communications receiving the 'Hosted Contact Center Service Provider of the Year' award from Mr. Vikram Idnani, CIO, Trent Limited, in the presence of Mr. Y. S. Shashidhar, Managing Director & Partner, MENASA, Frost & Sullivan
Mr. Mandar Mungee, Head – Renewals & Retention, India, Global Enterprise Solutions and Mr. Sunny Sharma, Sr. Product Management Specialist, Global Network, Cloud & Data Center Services, Tata Communications receiving the 'Enterprise Ethernet Provider of the Year' award from Mr. Keyur Desai, VP-IT Infrastructure & Projects Group, Essar Group, in the presence of Mr. Benoy CS, Director, Digital Transformation Practice, Frost & Sullivan
Mr. Rohit Arora, Head- India, Global Enterprise Solutions, Tata Communications receiving the 'Enterprise Telecom Service Provider of the Year – Large Enterprise Segment' award from Mr. Yagnesh Parikh, Executive Vice President & CTO, ICICI Securities, in the presence of Mr. Raghavendra Rao, Sr. VP, Frost & Sullivan
Mr. Sumit Mukhija, Head – Colocation Business, India, Tata Communications receiving the 'Third Party Datacenter Provider of the Year' award from Mr. Keyur Desai, VP-IT Infrastructure & Projects Group, Essar Group, in the presence of Mr. Benoy CS, Director, Digital Transformation Practice, Frost & Sullivan
Mr. Rajesh Menon, Head – Business Development, UCC (India & APAC), Tata Communications receiving the 'Enterprise VoIP Provider of the Year' award from Mr. Anil Kumar Kaushik, GM-IT & BI, Bharat Petroleum Corporation, in the presence of Mr. Raghavendra Rao, Sr. VP, Frost & Sullivan

Hewlett Packard Enterprise Introduces New Application Lifecycle Management Software for DevOps and Agile Environments

Business Wire India
Hewlett Packard Enterprise (NYSE: HPE) today announced the availability of HPE ALM Octane, an Application Lifecycle Management (ALM) software offering, designed to help customers accelerate their DevOps processes. This streamlined ALM solution leverages widely-used developer toolsets like Jenkins and GIT to bring continuous quality to lean, Agile, and DevOps-focused teams. HPE ALM Octane provides insights to developers and testers, helping them deliver applications quickly, without sacrificing quality or end-user experience.
 
To keep pace with a rapidly changing market landscape and deliver compelling customer experiences, organizations are building and enhancing software and mobile applications at lightning speed. This accelerating rate of change drives businesses to rethink how they optimize their internal software development processes. Application delivery management solutions that ensure on-going quality and scale at increased speed have not yet evolved fast enough to support development methodologies like Agile, Lean, and DevOps.
 
"At the core of successful business today, you will find agile, high-quality, high-performing applications that continuously provide engaging and intuitive user experiences,” said Saurabh Saxena, Country Director, Software, Hewlett Packard Enterprise India. "However, to rapidly deliver these remarkable applications, IT teams need to be equally agile and continuously deliver high-quality products. HPE ALM Octane is specifically designed for Agile and DevOps-ready teams, bringing a cloud-first approach that’s accessible anytime and anywhere, bolstered by big data-style analytics to help deliver speed, quality, and scale across all modes of IT.”
 
Guided by Analytics and an Open Architecture, HPE ALM Octane Drives Speed, Quality, and Scale
 
To improve product direction and execution, software development teams need products capable of integrating data from a wide array of developer and testing tools, to seamlessly report on the state of quality across the application delivery pipeline, and to enable big data-style algorithms to leverage lifecycle data. HPE ALM Octane achieves this for software developers to streamline production. Along with HPE ALM and Quality Center, HPE ALM Octane can bridge the gap for software developers and organizations who continue to use legacy methods of software development in existing projects to modern software development practices such as DevOps, lean, Agile, and more.
 
HPE ALM Octane is optimized for integration with widely adopted developer testing tools –leveraging Swagger-documented REST APIs – and an open platform architecture built on a layer of open source. While inherently open, HPE ALM Octane is designed to address the challenges associated with the scale required by enterprise software delivery. To accelerate application delivery across multiple teams, the solution provides visually guided and easily configured business rules and workflow.
 
HPE ALM Octane configures and manages automated testing within the context of a continuous integration pipeline, making it simple for developers to automatically view results and defects in context. In addition, through HPE ALM Octane’s open architecture, organizations can leverage a wide array of test frameworks from both HPE and third party due to the incorporation of continuous integration tools such as Jenkins and Team City.
 
Key features offered by HPE ALM Octane include:
 

  • Enhanced Open Source Dev/Test Toolchains– HPE ALM Octane, is integrated with a core set of widely adopted tools focused on test automation, collaboration and application deployment, which increase volume and shift testing left. Leveraging the strength of these tools, HPE ALM Octane adds value for cross-toolchain visibility and insight. The solution will support the following tools and frameworks:
    • Jenkins and TeamCity integration to trigger continuous integration and testing activities, discover tests, execute test runs, and maintain relationships and report results – including defects associated with each pipeline build.
    • GIT to provide manual tests script version management and managing tests in source code.
    • Business-Driven Development (BDD) via support of Gherkin to develop tests earlier in the design and development phases of the lifecycle; this helps streamline the use of automated testing from manual processes as tests are easily converted to automated scripts.
    • A wide array of test automation tools from HPE and Open Source including, HPE Unified Functional Testing, HPE LeanFT, HPE StormRunner Load, and Selenium that are executed via CI integration; and test activities, types and results which are continuously reported and linked to HPE ALM Octane application modules, builds and defects.
    • Swagger-documented REST APIs for straightforward third-party tool integration.
  • Continuous Quality for DevOps Software Delivery– Utilizes the continuous integration process and associated activities to capture, analyze, provide, and present intuitively actionable data for defect management and tracking.
  • Enhanced Collaboration with ChatOps– Proactively tracks rapidly evolving relationships between pipeline activity, application architecture and components, and state of quality. In addition, HPE ALM Octane tracks change between application components, backlog, builds, tests, and defects. Artifacts, status, and relationships are easily maintained through intelligent tagging and with ChatOps, collaboration becomes context rich and automatic.

 
“Hitachi Consulting provides leading digital enablement platforms to achieve our customer’s goals by focusing on exceptional operational capabilities and performance,” said Jonathon Wright, Director of Digital Engineering at Hitachi Consulting (@HIT_Consulting). “With Hewlett Packard Enterprise, and especially leveraging HPE ALM Octane, we look forward to bolstering our capacity to deliver digital services in dynamic application delivery development environments for the critical areas they’re looking to address – especially around DevOps processes.”
 
"Accelerating development and deployment across form factors — from cloud and native mobile to IoT including micro services — demands agile coordination across the software lifecycle," said Melinda Ballou, Program Director of IDC's (@IDC), Application Lifecycle & Executive Strategies service. "Each of these areas brings new challenges for developers. The sheer velocity and complexity of deployment needs for business innovation is changing how teams work to address design, speed, scale, continuous quality and integration with continuous test and continuous release. Management across disparate processes and leverage of open source is key."    
 
In addition to the launch of HPE ALM Octane, HPE is also announcing several new features to HPE functional and performance testing that support Agile, DevOps, and quality at scale. Please click here to read more.
 
Availability

Organizations can leverage HPE ALM Octane as a cloud-delivered service starting today. On-premise HPE ALM Octane installations will be available later in 2016.
 
Additionally, current HPE ALM and HPE Quality Center enterprise customers on support are entitled to the new offering as part of their active support contract.
 
Mobile Center updates will be introduced to help developers further increase mobile application quality and user experience optimization throughout the application lifecycle.
 
For more information on HPE ALM Octane, read our blog on All About the Apps, and to access a trial, click here.
 
Join HPE Software on LinkedIn and follow @HPE @HPE_Software and @HPE_ALM on Twitter.
 
About Hewlett Packard Enterprise

Hewlett Packard Enterprise is an industry-leading technology company that enables customers to go further, faster. With the industry’s most comprehensive portfolio, spanning the cloud to the data center to workplace applications, our technology and services help customers around the world make IT more efficient, more productive and more secure.

Lynparza (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer

Business Wire India

AstraZeneca presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with Lynparza (olaparib) maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial. These results support the previously reported benefits of olaparib in progression-free survival (PFS) compared to placebo, the primary endpoint of the trial.

 

A 27% reduction in risk of death compared to placebo was seen in the overall trial population (HR 0·73, 95% CI 0·55–0·96, nominal p=0.02483; median OS 29·8 vs 27·8 months), with greater reduction in the risk of death of 38% compared to placebo observed in patients with BRCA1/2 mutations (BRCAm) (HR 0·62, 95% CI 0·41–0·94, nominal p=0.02480; 34·9 vs 30·2 months).1 As this was the third analysis of survival, the nominal p-values did not meet the criterion for statistical significance and therefore the treatment effect observed for OS can only be considered descriptive. A number of patients continue to benefit from olaparib maintenance therapy, with 15% of BRCAm patients receiving olaparib for over five years.2

 

Jonathan Ledermann, Director of the Cancer Research UK & UCL Cancer Trials Centre and lead author of Study 19, said, “These results are extremely encouraging. The data show that some ovarian cancer patients receive benefit from this treatment for over 5 years, which is significant for patients with limited treatment options.”

 

The update from Study 19, presented at the American Society of Clinical Oncology (ASCO) congress in Chicago, is based on a 77% data maturity conducted after more than five years total follow-up, with an additional three years of follow-up since the previous analysis. Two interim analyses of OS from Study 19 have previously been conducted, at 38% data maturity (HR 0·94, 95% CI 0·63–1·39, p=0·75) and 58% data maturity (HR 0·88, 95% CI 0·64–1·21, p=0·44) in the overall trial population.2,3

 

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These results are a testament to the value of olaparib’s mode of action and the potential significance of targeting the DNA damage response (DDR) pathway, reinforcing our commitment to explore the full potential of DDR targeted treatments across a range of cancers.”

 

This update supports previously presented results on the primary endpoint of the trial of progression-free survival (PFS) which showed a statistically significant difference compared to placebo (HR 0·35, 95% CI 0·25–0·49, p<0.0001), with the greatest effect seen in the BRCAm subgroup (HR 0·18, 95% CI 0·10–0·31, p<0.0001).2 A significant improvement in time to first subsequent therapy or death (TFST) (HR 0·32, 95% CI 0·22-0·48, p<0.00001) and time to second subsequent therapy or death (TSST) (HR 0·41, 95% CI 0·28-0·62, p<0.00001) was also observed with maintenance olaparib compared with placebo, consistent with previously reported data on TFTS and TSST.2

 

There was no change to the overall safety profile and no new safety signals were reported for the patients remaining on treatment since the previous safety analysis. Serious adverse events were reported in 25 (18%) of 136 patients in the olaparib group and 11 (9%) of 128 patients in the placebo group. The most common serious adverse event was small intestinal obstruction (two [1%] patients in the olaparib group and three [2%] in the placebo group).2 The most common adverse events in patients who were treated for two years or more were nausea (olaparib: 24 patients [75%] vs placebo: 2 patients [40%]), fatigue (18 [56%] vs 2 [40%]), constipation (12 [38%] vs 1 [20%]) and vomiting (12 [38%] vs 0). These long-term safety findings are consistent with previous data from Study 19 and other clinical olaparib monotherapy studies.

 

Lynparza (olaparib) is the foundation of AstraZeneca’s industry-leading line of potential medicines in development targeting DNA damage response (DDR) mechanisms in cancer cells. DDR is a term describing the network of cellular pathways that minimise the daily impact of DNA damage. Currently, many cancers are known to have defects in DDR pathways, which makes them dependent on and therefore, highly sensitive to inhibition of the remaining DDR pathways. Targeting DDR deficiencies to preferentially kill cancer cells, while minimising the impact on normal cells, has potential for more selective, better tolerated therapies than chemotherapy that might improve survival in multiple cancers. AstraZeneca is developing a comprehensive pipeline of compounds that target molecular pathways across the DDR system. An extensive Phase III clinical trial programme investigating olaparib in BRCAm ovarian cancer patients (SOLO) is currently ongoing. Phase II and III studies in breast cancer, pancreatic cancer, and prostate cancer are also currently underway.4,5,6,7

 

– ENDS –

 

NOTES TO EDITORS

 

About Study 19

 

Study 19 was a Phase II, randomised, double-blind, placebo-controlled, multicentre trial, which evaluated the efficacy and safety of olaparibagainst placebo in relapsed, high grade serous ovarian cancer patients, involving 82 sites across 16 countries. Patients received oral olaparib maintenance monotherapy, at a dose of 400mg bid (capsules, manufactured by AstraZeneca) or matching placebo. Treatment continued until disease progression, provided that toxicities were manageable. The primary endpoint was progression-free survival. Overall survival, safety, tolerability, TFST and TSST were also assessed.

 

About olaparib

 

Lynparza (olaparib) is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DDR pathway deficiencies to preferentially kill cancer cells. Olaparib is the first PARP inhibitor to be approved by regulatory authorities in the EU and US for the treatment of women with BRCA-mutated (BRCAm) ovarian cancer.

 

About AstraZeneca in ovarian cancer

 

Worldwide, ovarian cancer is the 7th most commonly diagnosed cancer8 and the 8th most common cause of cancer death in women.9 The risk of developing ovarian cancer is increased in women with specific inherited genetic abnormalities, including BRCA mutations.AstraZeneca is committed to the continued development of our R&D portfolio for ovarian cancer, with a focus on improved care for all patients, including the development of targeted therapies for patients with specific gene mutations such as BRCA.

 

About AstraZeneca in Oncology

 

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least 6 new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.

 

By harnessing the power of four scientific platforms — immuno-oncology, the genetic drivers of cancer and resistance, DNA damage response and antibody drug conjugates — and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

 

About AstraZeneca

 

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal

 

References

 

1 Ledermann J et al. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago; 3-7 June 2016. Abstract available at: http://abstract.asco.org/176/AbstView_176_166142.htmlAccessed June 2016.

 

2 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-861.

 

3 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-1392.

 

4 National Institutes of Health. Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) Available at: https://clinicaltrials.gov/ct2/show/NCT02000622 Last accessed June 2016.

 

5 National Institutes of Health. Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) Available at: https://clinicaltrials.gov/ct2/show/NCT02032823 Last accessed June 2016.

 

6 Mateo J et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373:1697-1708.

 

7 National Institutes of Health. Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01924533 Last accessed June 2016.

 

8 Cancer Research UK. Ovarian cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics. Last accessed June 2016.

 

9 Cancer Research UK. Ovarian cancer mortality statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/mortality/ Last accessed June 2016.

 

 

QVC Inks Long-Term Capacity Renewal Moves to Centre of the Arc with SES

Business Wire India

SES S.A. (Euronext Paris:SESG) (LuxX:SESG) announced today that QVC has renewed a key, multi-year capacity deal and moved a significant block of its regional shopping channel content to the centre of the orbital arc, fast becoming the premier content distribution platform over North America.

 

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160606005521/en/

 

SES (Photo: Business Wire)

SES (Photo: Business Wire)

As part of the agreement, QVC, a world leading video and ecommerce retailer, has signed a capacity extension to deliver a major portion of its regional 24/7 shopping shows and exclusive product showcase lineup on the SES-3 satellite. The deal represents QVC’s steady migration to one of three SES satellites (SES-1, SES-3, AMC-18) hosting the next-generation, centre of the arc cable neighbourhood. SES-3 is also home to QVC Plus, the multichannel retailer’s newest US broadcast.

 

QVC has delivered much of its growing and increasingly tailored lineup of specialised shopping channels in North America and Europe over SES satellites for nearly 30 years.

 

“QVC provides consumers with an engaging and entertaining shopping experience across web, mobile, TV and social platforms,” explained Joe Micucci, Vice President of Broadcast Engineering for QVC. “We strive to provide a seamless and consistent experience across platforms, and our satellite distribution is a big part of this strategy. We have tapped SES’s next-generation cable neighbourhood, confident that it will provide decades of reliable programme delivery, much like SES has done since the early years of our network.”

 

“QVC has played a major role in redefining retail – checking out a dynamic and diverse range of products in the comfort of our homes, and at our fingertips on tablets and smartphones anywhere in the world,” said Steve Bunke, Vice President of North America Media Services for SES. “SES and QVC have developed a collaborative relationship aimed at keeping storefronts open for business 24/7 with reliable programming distribution and enabling QVC to innovate new, exciting retail opportunities around the globe.”

 

Follow us on:
Twitter: https://twitter.com/SES_Satellites
Facebook: https://www.facebook.com/SES.YourSatelliteCompany
YouTube: http://www.youtube.com/SESVideoChannel
Blog: http://www.ses.com/blog
SES Pictures are available under http://www.ses.com/21472913/Our_Pictures
SES White papers are available under http://www.ses.com/18681915/white-papers

 

About SES

 

SES (Euronext Paris:SESG) (LuxX:SESG) is the world-leading satellite operator with a fleet of more than 50 geostationary satellites. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators and business and governmental organisations worldwide.

 

SES stands for long-lasting business relationships, high-quality service and excellence in the satellite industry. The culturally diverse regional teams of SES are located around the globe and work closely with customers to meet their specific satellite bandwidth and service requirements.

 

SES holds a participation in O3b Networks, a next generation satellite network combining the reach of satellite with the speed of fibre.

 

Further information available at: www.ses.com.

 

 

 

 

MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20160606005521/en/

European Society of Anaesthesiology Partners with Patient Safety Movement to Lead the Movement to Zero Preventable Deaths in Europe

Business Wire India

The European Society of Anaesthesiology (ESA) and the Patient Safety Movement Foundation announced that on May 28, 2016 at the annual congress Euroanaesthesia 2016 in London, the ESA made a public commitment to lead the Patient Safety Movement in over 50 countries in Europe.

 

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160606005311/en/

 

“As clinicians, our number one focus is Patient Safety,” said Dr. Zeev Goldik, President of the European Society of Anaesthesiology. “Since its launch in 2010, the Helsinki Declaration on Patient Safety in Anaesthesiology has been signed and/or supported by regional and national anaesthesiology societies across the globe, from Europe, North America, Latin America, Australasia, Asia and Africa. Our Society was the initiator and one of the founding societies of the European Patient Safety Foundation (EUPSF) in 2013. We have been closely following the remarkable efforts made by the Patient Safety Movement. The Movement reached out to us as a partner and we accepted with a commitment to lead the movement in Europe to eliminate preventable patient deaths.”

 

“The time for action is now,” said Dr. Jannicke Mellin-Olsen, Secretary of the ESA, and a driving force for the Helsinki Declaration. “Europe is formed by a very diverse group of countries, governments, policies and regulations. As anaesthesiologists, we are taking care of the best interests of the patients whenever they are at their most vulnerable. We need to work at many levels, including inspiring everyone in the healthcare sector to take action and make their own personal commitment to patient safety and zero preventable deaths. We cannot leave this issue to someone else to solve. We are excited to formally begin our relationship with the Patient Safety Movement and complement our position as the European expert and leader in patient safety and quality of care. Anaesthesiologists have the key and leading role in the implementation of safer patient care in perioperative medicine, before, during and after surgery.”

 

“We thank the ESA for joining the Patient Safety Movement. ESA is a thoughtful and powerful organization that with over 32,000 members will make a huge difference in eliminating preventable deaths worldwide,” said Joe Kiani, Founder of Patient Safety Movement. Mr. Kiani continued, “What clinicians do is incredible; they provide the miracle of healing. Yet, due to lack of safety processes, some of the patients don't make it home. Their families will never be the same again, and sometimes the world will never be the same again. Preventable deaths in hospitals is the 3rd leading cause of death. We lose 3 million people each year! It's a tragedy 3 million times over again. Yet, it's a huge opportunity because by definition they are preventable. But, it won't get fixed by itself, and it won't get fixed by a handful of patient safety experts. It has to be fixed by each and every one of us. All of us in the healthcare ecosystem must act now! Each of us has to decide that we have to be the one to take on this burden and lead the charge to zero preventable deaths in our hospitals. We can't afford to lose another friend, family or neighbor before their time.”

 

European Society of Anaesthesiology

 

European Society of Anaesthesiology is a non-profit organisation dedicated to strengthening and unifying European anaesthesiology in the perioperative setting. It represents the medical speciality of anaesthesiology throughout Europe, through the drafting of guidelines, research and education with the aim of improving safer patient care and better outcomes. With more than 32,000 members from 108 countries across the globe, it has grown to become one of the largest and most influential anaesthesiology societies in the world and hosts one of the biggest and most innovative scientific meetings in Europe, Euroanaesthesia. The Society works closely with national anaesthesiology societies across Europe and further afield and the European Board of Anaesthesiology/UEMS, while establishing relationships with major international organisations from other related fields. It also monitors developments on the EU level which could have an impact on research and practice in anaesthesiology, with the best interests of the patient as its overriding goal. The European Society of Anaesthesiology aims for the highest standards of practice and safety in anesthesia, perioperative medicine, intensive care, critical emergency medicine and pain medicine through education, research and professional development. The ESA is the European Regional Section of the World Federation of Societies of Anaesthesiologists (WFSA) and is a member of Alliance for Biomedical Research in Europe (BioMed Alliance). The ESA organises the European Anaesthesiology Congresses: Euroanaesthesia and the Focus Meeting on Perioperative Medicine. Visit www.esahq.org.

 

About The Patient Safety Movement Foundation

 

More than 3,000,000 people worldwide, and 200,000 people in the US die every year in hospitals in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare, to reduce that number of preventable deaths to 0 by 2020 (0X2020) in the US and dramatically worldwide. Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems and solutions of patient safety. The Foundation also convenes the annual World Patient Safety, Science and Technology summit. The Summit presents specific, actionable solutions to meet patient safety challenges, encouraging medical technology companies to share the data for which their products are purchased, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions. Visit www.patientsafetymovement.org.

 

@0x2020 @ESA_HQ#patientsafety #0x2020

 

 

MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20160606005311/en/